Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Teglutik in amyotrophic lateral sclerosis
ChiCTR2500099817Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Teglutik in amyotrophic lateral sclerosis (ALS), sponsored by Peking University Third Hospital. Primary endpoint: ALS Functional Rating Scale-Revised (ALSFRS-R). Started Mar 2025; status: recruiting.
02
Drugs
Teglutik
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2500099817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099817.